Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1

Immunoglobulin G (IgG) molecules are glycosylated in CH2 at Asn297; the N-linked carbohydrates attached there have been shown to contribute to antibody (Ab) stability and various effector functions. The carbohydrate attached to the IgG constant region is a complex biantennary structure. Alterations in the structure of oligosaccharide have been associated with human diseases such as rheumatoid arthritis and osteoarthritis. To study the effects of altered carbohydrate structure on Ab effector function, we have used gene transfection techniques to produce mouse-human chimeric IgG1 Abs in the Chinese hamster ovary (CHO) cell line Lec 1, which is incapable of processing the high-mannose intermediate through the terminal glycosylation steps. We also produced IgG1 Abs in Pro-5, the wild-type CHO cell line that is the parent of Lec 1. The Pro-5-produced Ab (IgG1-Pro-5) was similar to IgG1-My 1, a myeloma-produced IgG1 Ab of the same specificity, in its biologic properties such as serum half-life, ability to effect complement-mediated cytolysis, and affinity for Fc gamma RI. Although the Lec 1-produced Ab, IgG1-Lec 1, was properly assembled and retained antigen specificity, it was incapable of complement-mediated hemolysis and was substantially deficient in complement consumption, C1q binding, and C1 activation. IgG1-Lec 1 also showed reduced but significant affinity for Fc gamma R1 receptors. The in vivo half-life of IgG1-Lec 1 was shorter than that of either the myeloma- or Pro-5-produced counterpart, with more being cleared during the alpha-phase and with more rapid clearance during the beta-phase. Clearance of IgG1-Lec 1 could be inhibited by the administration of yeast-derived mannan. Thus the uptake of IgG1-Lec 1 appears to be accelerated by the presence of terminally mannosylated oligosaccharide. Therefore, certain Ab functions as well as the in vivo fate of the protein are dramatically affected by altered carbohydrate structure. Expression of Igs in cell lines with defined glycosylation mutations is shown to be a useful technique for investigating the contribution of carbohydrate structure to Ab function.

[1]  S. Morrison,et al.  The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region , 1991, The Journal of experimental medicine.

[2]  J. Deisenhofer Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[3]  T. V. van Berkel,et al.  Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. , 1988, The Journal of biological chemistry.

[4]  M. Brüggemann,et al.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q , 1988, The Journal of experimental medicine.

[5]  P. Garred,et al.  Human IgG subclass pattern of inducing complement‐mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration , 1991, European journal of immunology.

[6]  G. Sármay,et al.  A protein structural change in aglycosylated IgG3 correlates with loss of huFcγR1 and hufcγR111 binding and/or activation , 1990 .

[7]  C. Channing,et al.  Role of the carbohydrate residues of human chorionic gonadotropin in binding and stimulation of adenosine 3',5'-monophosphate accumulation by porcine granulosa cells. , 1978, Endocrinology.

[8]  L. Nelles,et al.  Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer. , 1991, European journal of biochemistry.

[9]  D. Burton,et al.  Human antibody effector function. , 1992, Advances in immunology.

[10]  P. Stanley Glycosylation mutants of animal cells. , 1984, Annual review of genetics.

[11]  S. Morrison,et al.  Structural features of human immunoglobulin G that determine isotype- specific differences in complement activation , 1993, The Journal of experimental medicine.

[12]  D. Isenberg,et al.  Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. , 1992, The Journal of clinical investigation.

[13]  R. R. Robinson,et al.  Secretion of functional antibody and Fab fragment from yeast cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Matzuk,et al.  Expression of recombinant human choriogonadotropin in Chinese hamster ovary glycosylation mutants. , 1989, Molecular endocrinology.

[15]  M. J. Mattes Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. , 1987, Journal of the National Cancer Institute.

[16]  R. Owens,et al.  Purification and characterization of chimeric human IgA1 and IgA2 expressed in COS and Chinese hamster ovary cells. , 1993, Journal of immunology.

[17]  A. Shimizu,et al.  Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. , 1982, Journal of immunology.

[18]  R. Dwek,et al.  Immunoglobulin G as a glycoprotein. , 1986, Biochemical Society symposium.

[19]  P. Stanley Glycosylation mutants and the functions of mammalian carbohydrates , 1987 .

[20]  S L Morrison,et al.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.

[21]  J. Baynes,et al.  Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes. , 1980, The Journal of biological chemistry.

[22]  S. Gillies,et al.  Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. , 1991, Hybridoma.

[23]  B. Smedsrød,et al.  Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. , 1990, The Biochemical journal.

[24]  P. Stanley,et al.  Complementation between mutants of CHO cells resistant to a variety of plant lectins , 1977, Somatic cell genetics.

[25]  P. Heinrich,et al.  Involvement of various organs in the initial plasma clearance of differently glycosylated rat liver secretory proteins. , 1988, European journal of biochemistry.

[26]  A. Riggs,et al.  Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. , 1990, Cancer research.

[27]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Wigzell,et al.  Biological significance of carbohydrate chains on monoclonal antibodies. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S L Morrison,et al.  Production and properties of chimeric antibody molecules. , 1989, Methods in enzymology.

[30]  P. Casellas,et al.  Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. , 1986, European journal of biochemistry.

[31]  M A Kukuruzinska,et al.  Protein glycosylation in yeast. , 1987, Annual review of biochemistry.

[32]  R. Dwek,et al.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG , 1985, Nature.

[33]  J. Tite,et al.  Humanized monoclonal antibody CAMPATH‐1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell‐derived material , 1992, Clinical and experimental immunology.

[34]  T Miyamoto,et al.  Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. , 1989, The Journal of rheumatology.

[35]  D R Burton,et al.  Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. , 1985, Molecular immunology.

[36]  H. Lenz,et al.  Reconstitution of functionally active antibody directed against creatine kinase from separately expressed heavy and light chains in non-lymphoid cells. , 1987, Gene.

[37]  R. Jefferis,et al.  A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. , 1990, The Biochemical journal.

[38]  D. Phillips,et al.  The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. , 1983, Biochemical Society transactions.

[39]  C. Bindon,et al.  Complement activation by immunoglobulin does not depend solely on C1q binding , 1990, European journal of immunology.